期刊文献+

美国FDA右丙氧芬撤市决策及特点分析

The Characteristic Analysis of Withdrawal of Dextropropoxyphene in the US
下载PDF
导出
摘要 目的分析FDA对右丙氧芬撤市事件的处理过程及特点。方法运用文献研究方法,通过查阅国外文献,从右丙氧芬撤市的背景、FDA对右丙氧芬不良反应的调查及所采取的措施等方面进行研究。结果 FDA右丙氧芬撤市决定是基于实证的直接结果,FDA在右丙氧芬撤市之前进行了完善的风险管理,FDA重视风险沟通,为撤市提供了稳定的环境基础。结论学习和运用风险管理和循证理念是我国药品监管的当务之急。 Objective To analyze how FDA dealed with the withdrawal of dextropropoxyphene and its characteristics. Methods Analyze the background of the withdrawal of dextropropoxyphene,the investigation of adverse events of dextropropoxyphene and the measures taken by FDA by literature study.Results The withdrawal of dextroprop-oxyphene is the direct result of scientific evidence.The risk management of dextropropoxyphene is perfect before its withdrawal.FDA attaches importance to risk communication and provides a stable environment to the withdrawal of dextropropoxyphene.Conclusion Study and apply the risk management and evidence-based view is priority of our medicine management.
出处 《中国药物警戒》 2012年第3期152-155,共4页 Chinese Journal of Pharmacovigilance
关键词 FDA 右丙氧芬 撤市 FDA dextropropoxyphene withdrawal
  • 相关文献

参考文献8

  • 1董江萍,伍红艳.对含右丙氧芬镇痛药EMEA、FDA采取不同措施降低风险[N].中国医药报,2009:1-2.
  • 2FDA.Written Statement for the January 30,2009 Joint Meeting ofthe Anesthetic and Life Support Drugs Advisory Committee andthe Drug Safety and Risk Management Advisory Committee[EB/OL].[2009-05-01].http://www.fda.gov/AdvisoryCommittees/Commi-ttees MeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsA-dvisory Committee/ucm120018.htm.
  • 3Xanodyne Pharmaceuticals,Inc.History and Overview of the Safe-ty and Efficacy of Propoxyphene Products.Joint Meeting of theAnesthetic and Life Support Drugs Advisory Committee and DrugSafety and Risk Management Committee[EB/OL].[2009-01-30].http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ucm129313.pdf.
  • 4FDA Office of Surveillance and Epidemiology.Serious AdverseEvents of Propoxyphene and Darvocet[EB/OL].[2008-12-15].http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket DrugSafetyInformation for PatientsandProviders/UCM234301.pdf.
  • 5FDA.FDA Drug Safety Communication:FDA recommends a-gainst the continued use of propoxyphene[EB/OL].[2010-11-30].http://www.fda.gov/Drugs/DrugSafety/ucm234338.htm.
  • 6FDA.Propoxyphene Questions and Answers[EB/OL].[2009-07].http://www.fda.gov/Drugs/DrugSafety/Postmarket Drug SafetyInformationforPatientsandProviders/ucm170268.htm.
  • 7SFDA.国家食品药品监督管理局决定将含右丙氧芬的药品制剂逐步撤出我国市场[EB/OL].[2011-01-31].http://www.sda.gov.cn/WS01/CL0051/58315.html.
  • 8FDA.Strategic Plan for Risk Communication[EB/OL].[2009-09-30].http://www.fda.gov/About-FDA/Reports Manuals Forms/Reports/ucm183673.htm#defining.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部